Difficulty: Medium
Average Score: 69%
Practice
Clofibrate (Atromid-S) is the drug of choice for treatment of broad-beta hyperlipidemia (type III). This consideration is:
Correct answer
B
Rationale
The correct answer is B) FALSE. Clofibrate (Atromid-S) is not the drug of choice for the treatment of broad-beta hyperlipidemia (type III). The drug of choice for treating type III hyperlipidemia is gemfibrozil.
Clofibrate is more commonly used to reduce elevated levels of cholesterol and triglycerides in the blood, particularly in patients with hypercholesterolemia or hypertriglyceridemia. It belongs to the fibric acid derivative class of medications and works by increasing the breakdown of fats in the body.
Educationally, understanding the appropriate drug therapies for different types of hyperlipidemia is crucial in pharmacology. This knowledge helps healthcare providers make informed decisions when managing patients with lipid disorders, ensuring optimal treatment outcomes. It is important for students and professionals to be familiar with the specific indications, contraindications, and mechanisms of action of various lipid-lowering agents to provide safe and effective care to patients.
Clofibrate is more commonly used to reduce elevated levels of cholesterol and triglycerides in the blood, particularly in patients with hypercholesterolemia or hypertriglyceridemia. It belongs to the fibric acid derivative class of medications and works by increasing the breakdown of fats in the body.
Educationally, understanding the appropriate drug therapies for different types of hyperlipidemia is crucial in pharmacology. This knowledge helps healthcare providers make informed decisions when managing patients with lipid disorders, ensuring optimal treatment outcomes. It is important for students and professionals to be familiar with the specific indications, contraindications, and mechanisms of action of various lipid-lowering agents to provide safe and effective care to patients.